Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Application of microarray technology in psychotropic drug trials.

Greer M Murphy1

  • 1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305-5485, USA. gmurphy@leland.stanford.edu

Journal of Psychopharmacology (Oxford, England)
|June 21, 2006
PubMed
Summary

Microarray-based CYP2D6 genotyping predicted drug levels for nortriptyline but not adverse events for newer antidepressants like paroxetine or mirtazapine. This highlights the complexity of pharmacogenetics in psychotropic drug treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression.

Translational psychiatry·2018
Same author

ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

The American journal of psychiatry·2015
Same author

Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2015
Same author

APOE-epsilon4 and aging of medial temporal lobe gray matter in healthy adults older than 50 years.

Neurobiology of aging·2014
Same author

BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression.

Pharmacogenetics and genomics·2013
Same author

Influences of APOE ε4 and expertise on performance of older pilots.

Psychology and aging·2011

Area of Science:

  • Pharmacogenetics
  • Genomics
  • Psychiatry

Background:

  • Microarrays enable detection of numerous DNA polymorphisms for pharmacogenetic prediction in psychotropic drug trials.
  • The CYP2D6 gene, encoding debrisoquine hydroxylase (DH), is crucial for metabolizing many psychotropic medications.

Purpose of the Study:

  • To evaluate the utility of CYP2D6 genotyping using microarrays in predicting treatment outcomes for psychotropic drugs.
  • To assess if CYP2D6 genotype predicts nortriptyline plasma concentrations and adverse event profiles in geriatric patients.

Main Methods:

  • Utilized microarrays to genotype common CYP2D6 polymorphisms in patient cohorts.
  • Assessed CYP2D6 genotype's ability to predict plasma concentrations of nortriptyline.
  • Examined the association between CYP2D6 genotype and adverse event discontinuations or severity for paroxetine and mirtazapine.

Related Experiment Videos

Main Results:

  • CYP2D6 genotypes successfully predicted plasma steady-state concentrations of nortriptyline in geriatric depression patients.
  • However, CYP2D6 genotypes did not predict discontinuations due to adverse events or their severity in patients treated with paroxetine or mirtazapine.
  • Pharmacokinetic factors influenced by CYP2D6 appear less critical for modern antidepressants compared to pharmacodynamic factors.

Conclusions:

  • CYP2D6 genotyping via microarrays shows potential for predicting outcomes with some psychotropics (e.g., nortriptyline) but not others (e.g., paroxetine, mirtazapine).
  • Pharmacodynamic factors may play a more significant role than CYP2D6-mediated pharmacokinetics for newer antidepressants.
  • The optimal approach for pharmacogenetic discovery—genome-wide versus hypothesis-driven—remains debated.